Amgen (AMGN) Tops Q2 EPS by 41c, Issues In-Line Guidance

Amgen (NASDAQ: AMGN) reported Q2 EPS of $4.25, $0.41 better than the analyst estimate of $3.84. Revenue for the quarter came in at $6.2 billion versus the consensus estimate of $6.18 billion.

GUIDANCE:

Amgen sees FY2020 EPS of $15.10-$15.75, versus the consensus of $15.64. Amgen sees FY2020 revenue of $25-25.6 billion, versus the consensus of $25.45 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• Nebius soars on second quarter revenue beat
• Sutro Biopharma Inc. (STRO) Misses Q2 EPS by 13c
• Fervo Energy Company (FRVO) Reports Q2 Loss of $0.38